Atorvastatin Calcium; Ezetimibe Patent Expiration
Atorvastatin Calcium; Ezetimibe is Used for lowering cholesterol levels in individuals with primary hyperlipidemia, mixed hyperlipidemia, or homozygous familial hypercholesterolemia. It was first introduced by Organon Llc A Sub Of Organon And Co
Atorvastatin Calcium; Ezetimibe Patents
Given below is the list of patents protecting Atorvastatin Calcium; Ezetimibe, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Liptruzet |
USRE42461 (Pediatric) | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr 25, 2017
(Expired) | Organon |
Liptruzet |
US5969156 (Pediatric) | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jan 08, 2017
(Expired) | Organon |
Liptruzet | USRE42461 | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct 25, 2016
(Expired) | Organon |
Liptruzet | US5969156 | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jul 08, 2016
(Expired) | Organon |
Liptruzet |
US5686104 (Pediatric) | Stable oral CI-981 formulation and process of preparing same |
May 11, 2015
(Expired) | Organon |
Liptruzet | US5686104 | Stable oral CI-981 formulation and process of preparing same |
Nov 11, 2014
(Expired) | Organon |
Liptruzet |
US5846966 (Pediatric) | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Mar 21, 2014
(Expired) | Organon |
Liptruzet | US5846966 | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Sep 21, 2013
(Expired) | Organon |
Atorvastatin Calcium; Ezetimibe's Family Patents

Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List